Forest Ray
Articles Authored by Forest Ray
The company sees a clearer path to clinical validation and reimbursement through molecules that more directly measure how drugs affect the brain.
The firm stopped billing Medicare while implementing changes required by an updated billing article and plans to lay off 12 percent of its workforce.
Test Volumes Drive Natera Q1 Revenues Up 25 Percent
Revenues rose nearly 25 percent year over year, and the firm raised its revenue guidance for the year to between $995 million and $1.02 billion.
Myriad Genetics Revenues Grow 10 Percent, Beating Wall Street Estimate
Strong test volume growth drove the revenue increase, while net loss more than doubled year over year.
Australia's Genetic Technologies Seeks Private Payor Coverage to Bring Polygenic Risk Tests to US
Premium
The company plans pilot studies with several private insurers to support coverage for its suite of combined clinical and polygenic risk tests.
Myriad Genetics Q4 Revenues Rise 11 Percent on Higher Test Volumes
Myriad finished the three months ended Dec. 31 with $177.8 million in revenues compared to $160.8 million for the same quarter in 2021, beating analysts' average estimate of $169.5 million.
Natera Q4, Full-Year Revenues Rise on Increased Product Sales, Test Volume
Test volumes rose by nearly 28 percent year over year to approximately 559,700 tests in Q4 2022.
CareDx Q4, Full-Year Revenues Rise on Back of Cash Collections, Test Volumes
CareDx finished the three months ended Dec. 31 with $82.4 million in revenues compared to $79.2 million for the same quarter in 2021, narrowly beating analysts' average estimate of $81.7 million.
The Canadian company plans to test the clinical utility of its targeted 90-marker panel in monitoring patient response to therapy.
Ampel will use the signature to develop FibroGene, a fibromyalgia blood test that the company expects to launch next year.